Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
- Development stage
- Unknown
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Foclivia** is an egg-derived, monovalent, inactivated surface-antigen vaccine for pandemic influenza A(H5N1). It contains haemagglutinin and neuraminidase antigens from the A/Vietnam/1194/2004(H5N1) strain and the oil-in-water adjuvant MF59C.1. The vaccine primes adaptive immune responses, including protective antibody production against H5N1 viral surface antigens, while MF59 enhances the magnitude of the immune response. It is authorised in the European Union for prophylaxis of influenza in an officially declared pandemic situation and is administered intramuscularly as a two-dose schedule separated by at least three weeks.
- Brand names
- Foclivia
- Other names
- A/Vietnam/1194/2004 (H5N1) virus surface inactivated antigen
02
Targets
H5 HA (Influenza A hemagglutinin H5)Neuraminidase (Influenza A virus strain A/Vietnam/1194/2004 (H5N1))
Beyond the preview
Go deeper on pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted).